TNG Transgene SA

2024 Half-Year Financial Report

2024 Half-Year Financial Report

2024 Half Year Financial Report

Attachment



EN
24/09/2024

Underlying

TNGTransgene SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Transgene SA

 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene and NEC Present New Data Confirming Clinical Proof of Princi...

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free TG4050 induced specific and sustained immune responses. A Phase II part is now enrolling patients internationally to build on this promising outcome Strasbourg, France & Tokyo, Japan, November 7, 2024, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a b...

November 7, 2024 1 EN
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene et NEC présentent de nouvelles données confirmant la preuve ...

Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024 Les données de suivi médian à 24,1 mois présentées au SITC 2024 montrent que tous les patients traités avec TG4050 en situation adjuvante après chirurgie et chimiothérapie standard sont toujours en rémission clinique et sans récidive TG4050 induit des réponses immunitaires persistantes et spécifiques. Une partie Phase II inclut actuellement des patients dans plusieurs pays pour confirmer ces données prometteu...

November 7, 2024 1 EN
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene Reports Business, Pipeline and Financial Update for Q3 2024

Transgene Reports Business, Pipeline and Financial Update for Q3 2024 TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, France, November 7, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides its business update and financial position for the quarter ending September 30, 2024. Key events and upcoming milestones ...

November 7, 2024 1 EN
Jamila El Bougrini ... (+2)
  • Jamila El Bougrini
  • Thibaut Voglimacci-Stephanopoli
11/07/24 November 7, 2024 1 FR
 PRESS RELEASE
Free
TNG TRANSGENE SA

Transgene and ProBioGen Join Forces to Advance Individualized Cancer V...

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development Strasbourg (France), Berlin (Germany), November 5, 2024, 7:30 a.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading CDMO in biologics, vaccines and viral vectors, announce that the companies have entered into a license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line. This partnership aims to add value by combining ProBioGen’s specific production technology with the manufacturing ...

November 5, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch